Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Fundamental Analysis of ERIS Lifesciences Ltd

About the Company - ERIS Lifesciences Ltd

Eris Lifesciences Ltd. is a Public Limited Listed company incorporated on 25/01/2007 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24232GJ2007PLC049867 and registration number is 049867. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1215.73 Cr. and Equity Capital is Rs. 13.59 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsShivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Ahmedabad Gujarat 380054complianceofficer@erislifesciences.com
http://www.eris.co.in
Management
NamePosition Held
Mr. Amit BakshiChairperson & Managing Director
Mr. Krishnakumar VaidyanathanCOO & Executive Director
Mr. Inderjeet Singh NegiExecutive Director
Mr. Kaushal ShahExecutive Director
Mr. Rajeev DalalIndependent Director
Mr. Vasudevan SujeshIndependent Director
Ms. Kalpana UnadkatIndependent Director
Mr. Prashant GuptaIndependent Director

Eris Lifesciences Ltd. Share Price Update

Share PriceValue
Today₹943.10
Previous Day₹940.85

Basic Stock Data of ERIS Lifesciences Ltd

Market Cap 12,830 Cr.
Current Price 943
High / Low972/551
Stock P/E34.0
Book Value 177
Dividend Yield0.78 %
ROCE16.7 %
ROE18.0 %
Face Value 1.00

ERIS Lifesciences Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales330310278349360332306399461423403467505
Expenses205203184223220210209269309286284297324
Operating Profit1251079512714012297129151137119170181
OPM %38%35%34%36%39%37%32%32%33%32%30%36%36%
Other Income2326758352113
Interest001111177391716
Depreciation11111115151718232930354142
Profit before tax11699851171311098510112110776112126
Tax %7%9%19%9%9%8%6%8%1%6%19%17%3%
Net Profit108906810711810180931191006194122
EPS in Rs7.936.645.037.868.717.415.916.968.857.494.816.989.07

ERIS Lifesciences Ltd Quarterly Chart

ERIS Lifesciences Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales2743935095465977508569821,0741,2121,3471,6851,798
Expenses2153074144274254805336377027818581,1461,191
Operating Profit598695118172269322345372431489539607
OPM %21%22%19%22%29%36%38%35%35%36%36%32%34%
Other Income119732526311292298
Interest11000111232242646
Depreciation3351620232636504365117148
Profit before tax558398109154270312317331394442405421
Tax %33%30%28%18%13%9%6%8%11%10%8%8%
Net Profit37587189135247295291297355406374378
EPS in Rs2,686.554,232.735,121.456,489.459,714.1817.9521.3921.1521.8426.1629.8828.1028.35
Dividend Payout %0%0%0%0%63%0%0%0%13%21%20%26%

ERIS Lifesciences Ltd Profit & Loss Yearly Chart

ERIS Lifesciences Ltd Growth

Compounded Sales Growth
10 Years::16%
5 Years::15%
3 Years::16%
TTM::20%

ERIS Lifesciences Ltd Growth

Compounded Profit Growth
10 Years::20%
5 Years::5%
3 Years::8%
TTM::-4%

ERIS Lifesciences Ltd Growth

Stock Price CAGR
10 Years::%
5 Years::9%
3 Years::21%
1 Year::38%

ERIS Lifesciences Ltd Growth

Return on Equity
10 Years::27%
5 Years::23%
3 Years::22%
Last Year::18%

ERIS Lifesciences Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital000001414141414141414
Reserves481061762662995538481,1371,2831,5631,8952,1822,398
Borrowings5311013771760784877830
Other Liabilities4963949198124170175205202233337634
Total Liabilities1021722713573976921,4081,5021,5021,7852,2263,4103,875
Fixed Assets23277572712327717618758549182,5682,520
CWIP0000000342272258
Investments134784167190303365356782945203722
Other Assets65981121191361572713835446367617831,275
Total Assets1021722713573976921,4081,5021,5021,7852,2263,4103,875

ERIS Lifesciences Ltd Reserves and Borrowings Chart

ERIS Lifesciences Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 30389090131200235223271375378292
Cash from Investing Activity -19-36-83-92-44-184-590-5123-323-320-975
Cash from Financing Activity -10-3-20-84-24363-221-335-82-45688
Net Cash Flow1-15-24-88-360-30145

ERIS Lifesciences Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days191516161624283153424463
Inventory Days166214166223178195178196148145166136
Days Payable13310913814292134247200213157166129
Cash Conversion Cycle52120439710284-4028-12304470
Working Capital Days1831715923-13-1759647692
ROCE %98%64%47%53%60%34%26%25%27%25%17%

ERIS Lifesciences Ltd Financial Efficiency Indicators Chart

No valid data available for the Shareholding

ERIS Lifesciences Ltd Shareholding Pattern Chart

No. of ERIS Lifesciences Ltd Shareholders

ERIS Lifesciences Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
HDFC Small Cap Fund - Regular Plan50987131.89438.23
UTI Flexi Cap Fund25730670.91221.16
Franklin India Smaller Companies Fund17109001.52147.05
Aditya Birla Sun Life Equity Hybrid 95 Fund13680301.7117.58
UTI Value Fund10291261.1988.45
HSBC Midcap Fund9625801.0382.73
HDFC Large and Mid Cap Fund - Regular Plan6750000.4958.02
UTI Mid Cap Fund5916120.5850.85
Tata ELSS Tax Saver Fund5120001.2744.01
UTI Dividend Yield Fund4500001.2638.68

ERIS Lifesciences Ltd ROCE Trend

ERIS Lifesciences Ltd EPS Trend

ERIS Lifesciences Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue1.001.001.001.001.00
Basic EPS (Rs.)28.1029.8926.1621.6121.15
Diluted EPS (Rs.)28.0729.8826.1421.5921.13
Cash EPS (Rs.)36.1234.6129.3225.5423.81
Book Value[Excl.RevalReserv]/Share (Rs.)163.30140.35116.1095.4784.99
Book Value[Incl.RevalReserv]/Share (Rs.)163.30140.35116.1095.4784.99
Revenue From Operations / Share (Rs.)123.9299.1089.2579.1071.42
PBDIT / Share (Rs.)40.2937.6032.3528.2627.39
PBIT / Share (Rs.)31.6832.8429.1924.5624.74
PBT / Share (Rs.)29.7632.5329.0524.4023.08
Net Profit / Share (Rs.)27.5129.8526.1621.8421.17
NP After MI And SOA / Share (Rs.)28.1029.8826.1621.8421.15
PBDIT Margin (%)32.5137.9336.2435.7338.34
PBIT Margin (%)25.5633.1332.7031.0534.64
PBT Margin (%)24.0132.8232.5530.8532.31
Net Profit Margin (%)22.2030.1229.3027.6029.64
NP After MI And SOA Margin (%)22.6730.1429.3027.6029.60
Return on Networth / Equity (%)17.4021.2822.5222.8725.27
Return on Capital Employeed (%)13.3621.5323.7624.0327.26
Return On Assets (%)10.4217.8719.3519.1018.71
Long Term Debt / Equity (X)0.290.020.000.000.00
Total Debt / Equity (X)0.370.020.000.000.00
Asset Turnover Ratio (%)0.520.610.670.670.61
Current Ratio (X)1.733.142.802.911.90
Quick Ratio (X)1.432.552.232.491.63
Inventory Turnover Ratio (X)1.261.311.481.040.83
Dividend Payout Ratio (NP) (%)26.1520.1021.0213.140.00
Dividend Payout Ratio (CP) (%)20.0117.3418.7511.230.00
Earning Retention Ratio (%)73.8579.9078.9886.860.00
Cash Earning Retention Ratio (%)79.9982.6681.2588.770.00
Interest Coverage Ratio (%)20.94123.26243.78177.5116.45
Interest Coverage Ratio (Post Tax) (%)15.3098.87198.08138.1413.72
Enterprise Value (Cr.)8575.569359.518168.964936.178868.07
EV / Net Operating Revenue (X)5.096.956.744.609.03
EV / EBITDA (X)15.6518.3118.6012.8623.55
MarketCap / Net Operating Revenue (X)4.626.956.774.669.02
Retention Ratios (%)73.8479.8978.9786.850.00
Price / BV (X)3.544.915.213.867.70
Price / Net Operating Revenue (X)4.626.956.774.669.02
EarningsYield0.040.040.040.050.03

ERIS Lifesciences Ltd Profitability Ratios (%)

ERIS Lifesciences Ltd Liquidity Ratios

ERIS Lifesciences Ltd Liquidity Ratios (%)

ERIS Lifesciences Ltd Interest Coverage Ratios (%)

ERIS Lifesciences Ltd Valuation Ratios

Fair Value of ERIS Lifesciences Ltd Stock

Fair Value: ₹1091.69

The stock is undervalued by 15.77% compared to the current price ₹943

*This is not Investment Advice

Strength and Weakness of ERIS Lifesciences Ltd Stock

StrengthWeakness

The company has shown consistent growth in sales and profit over the years.

The stock has a low average ROCE, which may not be favorable.

The stock has a high average Working Capital Days, which may not be favorable.

The stock has a high average Cash Conversion Cycle, which may not be favorable.

The company has higher borrowings compared to reserves, which may suggest financial risk.

Related Posts